Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) posted its quarterly earnings results on Monday. The biotechnology company reported ($1.07) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.36, Briefing.com reports. The company had revenue of $17.97 million during the quarter, compared to analysts’ expectations of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. The firm’s revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.27) EPS.

Enanta Pharmaceuticals Stock Down 4.8 %

Shares of Enanta Pharmaceuticals stock traded down $0.63 during trading hours on Wednesday, hitting $12.37. 174,451 shares of the company’s stock traded hands, compared to its average volume of 217,724. Enanta Pharmaceuticals has a twelve month low of $8.08 and a twelve month high of $18.82. The company has a market cap of $261.98 million, a PE ratio of -2.08 and a beta of 0.60. The stock has a 50 day simple moving average of $13.57 and a 200-day simple moving average of $13.76.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the transaction, the insider now directly owns 23,988 shares in the company, valued at approximately $361,499.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Scott T. Rottinghaus sold 4,299 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares in the company, valued at approximately $370,926.36. The disclosure for this sale can be found here. Insiders sold a total of 16,940 shares of company stock worth $246,181 in the last 90 days. 13.64% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ENTA has been the subject of several research reports. JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday. JMP Securities reduced their target price on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 7th. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $18.83.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.